Advancing priority research on the middle east respiratory syndrome coronavirus

Journal of Infectious Diseases

Volumn 209, Issue 2, 2014, Pages 173-176

  Hui, David S ^a   Zumla, Alimuddin ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cornavirus; Diagnostics; MERS Cov; Middle East, research priorities; Respiratory tract infections; Treatment

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; CYCLOPHILIN INHIBITOR; DIPEPTIDYL PEPTIDASE IV; INTERFERON; LOPINAVIR; MYCOPHENOLIC ACID; NELFINAVIR; NITAZOXANIDE; RIBAVIRIN; VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; CAUSE OF DEATH; CORONAVIRUS; DISEASE CARRIER; DISEASE SEVERITY; FRANCE; GERMANY; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOFLUORESCENCE; INFLUENZA; ITALY; JORDAN; KINETICS; LOWER RESPIRATORY TRACT; MEDICAL EDUCATION; MEDICAL RESEARCH; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; NOTE; NUCLEOTIDE SEQUENCE; OMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH; QATAR; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; SAUDI ARABIA; SEROLOGY; TUNISIA; UNITED ARAB EMIRATES; UNITED KINGDOM; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 84891506244     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit591     Document Type: Note

References (34)

1. Severe respiratory illness associated with a novel coronavirus-Saudi Arabia and Qatar, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:820
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20
3. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J Virol 2013; 87: 7790-2
4. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis 2013; 13:752-61
5. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369: 407-16
6. WHO update. Middle East respiratory syndrome coronavirus (MERS-CoV) - update. 29 October, 2013. http://www.who.int/csr/don/ 2013-11-11-coronavirus/en/ index.html. Accessed 15 November 2013
7. Updated information on the epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection and guidance for the public, clinicians, and public health authorities, 2012-2013. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2013; 62:793-6
8. Memish ZA, Zumla AI, Al-Hakeem RF, Al- Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013; 368:2487-94
9. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 2013; 369:884-6
10. Cotten M, Watson SJ, Kellam P, et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive genomic study. Lancet 2013. doi:pii: S0140-6736(13)61887-5. 10.1016/ S0140-6736(13)61887-5. [Epub ahead of print].
11. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 2013; 18:1-7
12. Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: A report of nosocomial transmission. Lancet 2013; 381:2265-72
13. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-4
14. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; 19:11: Doi: 10.3201/eid1911.131172, in press
15. Gierer S, Bertram S, Kaup F, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013; 87:5502-11
16. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci USA 2009; 106:5871-6
17. Reusken CB, Haagmans BL, Muller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study. Lancet Infect Dis 2013; 13:859-66
18. Crossley BM, Mock RE, Callison SA, Hietala SK. Identification and characterization of a novel alpaca respiratory coronavirus most closely related to the human coronavirus 229E. Viruses 2012; 4:3689-700
19. Aburizaiza AS, Mattes FM, Azhar E, et al. Investigation of anti-MERS-cornavirus antibodies in blood donors and abbatoir workers in Jeddah and Makkah, Kingdom of Saudi Arabia, fall 2012. J Infect Dis 2014; 209:243-6
20. Gautret P, Charrel R, Belhouchat K, et al. Lack of nasal carriage of novel corona virus (HCoV-EMC) in French Hajj pilgrims returning from the Hajj 2012, despite a high rate of respiratory symptoms. Clin Microbiol Infect 2013; 19:E315-7
21. Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: Estimation of pandemic risk. Lancet 2013; 382:694-9
22. Bates M, Mudenda V, Mwaba P, Zumla A. Deaths due to respiratory tract infections in Africa: A review of autopsy studies. Curr Opin Pulm Med 2013; 19:229-37
23. Yao Y, Bao L, Deng W, et al. An animal model of MERS produced by infection of Rhesus macaques with MERS coronavirus. J Infect Dis 2014; 209:236-42
24. deWit E, Rasmussen AL, Falzaranoa D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci USA 2013; 110: 16598-603
25. Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV) - possible lessons from a systematic review of SARSCoV therapy. Int J Infect Dis 2013; 17: E792-8. doi:10.1016/j.ijid.2013.07.002. Epub 2013 Aug 29
26. Chan JFW, Chan KH. Broad spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67: 606-16
27. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV- infected rhesus macaques. Nat Med 2013; 19:1313-7
28. De Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 2011; 92:2542-8
29. Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses 2013; 5:1250-60
30. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-8
31. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-6
32. Hung IF, To KK, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144: 464-73
33. Zumla A. Equitable partnerships for tackling killer infectious diseases. Lancet Glob Health 2013. http://globalhealth.thelancet.com/2013/ 07/26/equitable-partnerships-tackling-killerinfectious- diseases-accessed. Accessed 7 October 2013
34. Rambaut A. Novel human betacoronavirus molecular evolutionary analyses. http:// epidemic.bio.ed.ac.uk/coronavirusesaccessed. Accessed 6 October 2013